PAHC · Phibro Animal Health Corp
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2027 (G) | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | $1.52B | $1.3B | $1.02BG | $977.89MG | $942.26M | $833.35M | $800.35M | $828M | $819.98M | $764.28M | $751.53M | $748.59M | $691.91M | $653.15M | $654.1M | |
| — | -$18.3M | — | — | — | -$15.32M | -$11.88M | -$12.88M | -$12.86M | -$11.78M | -$11.91M | -$14.91M | -$16.59M | -$14.31M | -$29.77M | $35.63M | — | |
| — | — | $1.01B | $896.27M | $704.59M | $679.65M | $656.86M | $561.97M | $543.47M | $563.37M | $553.1M | $516.04M | $512.49M | $515.31M | $487.5M | $474.19M | $489.96M | |
| — | — | $512.52M | $399.94M | $313.09M | $298.24M | $285.4M | $271.38M | $256.88M | $264.62M | $266.88M | $248.24M | $239.03M | $233.28M | $204.41M | $178.96M | $164.14M | |
| — | — | 33.76% | 30.85% | 30.77% | 30.5% | 30.29% | 32.56% | 32.1% | 31.96% | 32.55% | 32.48% | 31.81% | 31.16% | 29.54% | 27.4% | 25.09% | |
| — | — | $24.55M | $23.73M | $29.19M | $24.4M | $20.83M | $17.76M | $13.74M | $12.09M | $10M | $9.44M | $11.03M | $9.51M | $8.21M | $6.64M | $7.19M | |
| — | — | — | — | — | — | — | — | — | $38.45M | $33.42M | $29.63M | — | — | — | — | — | |
| — | — | $318.12M | $289.48M | $259.78M | $226.39M | $206.41M | $196.51M | $187.69M | $181.4M | $167.95M | $150.31M | $153.29M | $145.61M | $140.62M | $122.23M | $114.81M | |
| — | — | $6.88M | $7.84M | $9.66M | $9.7M | $8.92M | $8.72M | $8.87M | $6.09M | $5.85M | $5.95M | $5.56M | $4.56M | $4.9M | $4.11M | $3.05M | |
| — | — | $51.51M | $45.61M | $36.18M | $34.01M | $32.71M | $31.89M | $32.34M | $27.56M | $26.94M | $26M | $23.45M | $21.6M | $21.45M | $19.02M | $17.53M | |
| — | — | — | — | $366K | — | — | — | $425K | — | — | — | — | — | — | — | — | |
| — | — | $194.4M | $110.47M | $53.32M | $71.85M | $78.99M | $74.87M | $69.19M | $83.23M | $98.93M | $97.93M | $85.74M | $87.67M | $63.79M | $56.73M | $49.33M | |
| — | — | 12.81% | 8.52% | 5.24% | 7.35% | 8.38% | 8.98% | 8.65% | 10.05% | 12.06% | 12.81% | 11.41% | 11.71% | 9.22% | 8.69% | 7.54% | |
| — | — | $245.91M | $156.07M | $89.49M | $105.86M | $111.69M | $106.75M | $101.54M | $110.79M | $125.87M | $123.94M | $109.2M | $109.27M | $85.25M | $75.75M | $66.85M | |
| — | — | $46.42M | $37.22M | $23.01M | $18.68M | $12.69M | $13.72M | $14.61M | $13.68M | $13.6M | — | — | $14.55M | $29.89M | $31.38M | $31.44M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $119K | $142K | $281K | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -$151K | $400K | |
| — | — | $137.35M | $67.99M | $10.92M | $54.07M | $72.33M | $66.47M | $55.51M | $71.51M | $88.07M | $80.54M | $76.76M | $78.76M | $6.31M | $17.85M | $13.11M | |
| — | — | $37.63M | $19.73M | $8.5M | $21.47M | $23.15M | $12.08M | $21.96M | $16.79M | $23.19M | $15.93M | -$5.97M | $18.48M | $9.44M | -$7.04M | $6.14M | |
| — | — | $99.72M | $48.26M | $2.42M | $32.61M | $49.18M | $54.39M | $33.55M | $54.71M | $64.88M | $64.62M | $82.73M | $60.28M | -$3.13M | $24.89M | $6.98M | |
| — | — | 6.57% | 3.72% | 0.24% | 3.33% | 5.22% | 6.53% | 4.19% | 6.61% | 7.91% | 8.45% | 11.01% | 8.05% | -0.45% | 3.81% | 1.07% | |
| — | — | $99.72M | $48.26M | $2.42M | $32.61M | $49.18M | $54.39M | $33.55M | — | — | — | — | — | — | — | — | |
| — | — | $117.66M | $47.77M | -$6.9M | $39.51M | $43.36M | $69.48M | -$10.65M | $45.02M | $43.84M | $70.96M | $72.54M | $28.74M | -$5.42M | $22.08M | -$19.36M | |
| USD/shares | — | — | $2.46 | $1.19 | $0.06 | $0.81 | $1.21 | $1.34 | $0.83 | $1.35 | $1.61 | $1.63 | $2.11 | $1.55 | -$0.10 | $0.82 | — |
| USD/shares | $2.98 – $3.22 | — | $2.43 | $1.19 | $0.06G | $0.81G | $1.21 | $1.34 | $0.83 | $1.35 | $1.61 | $1.61 | $2.07 | $1.51 | -$0.10 | $0.82 | — |
| shares | — | — | 40.55M | 40.52M | 40.5M | 40.5M | 40.5M | 40.47M | 40.45M | 40.41K | 40.18K | 39.52K | 39.25K | 38.97M | 32.19M | 30.46K | 30.46K |
| shares | — | — | 40.96M | 40.68M | 40.52M | 40.5M | 40.5M | 40.5M | 40.5M | 40.52K | 40.39K | 40.04K | 39.96K | 39.82M | 32.19M | 30.46K | 30.46K |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2013–FY2026: $245.88M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 45 similar-size Drug Manufacturers - Specialty & Generic companies (of 97 listed).
EV/Adj. EBITDA uses the company-stated “Adjusted EBITDA”, extracted from the reconciliation in its SEC filings — the company's own non-GAAP definition, not an XBRL-tagged figure.
Valuation over time computed as of each quarter's filing date
EV/Adj. EBITDA uses the company-stated “Adjusted EBITDA”, extracted from the reconciliation in its SEC filings as it existed at each sample date — the company's own non-GAAP definition, not an XBRL-tagged figure. Each point's tooltip names its TTM or fiscal-year basis.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Animal Health | $1,162,219,000 | $962,796,000 | $706,482,000 | $659,851,000 | $607,055,000 | $545,716,000 | $526,904,000 | $531,974,000 |
| Mineral Nutrition | $282,341,000 | $253,240,000 | $243,663,000 | $242,656,000 | $259,512,000 | $220,560,000 | $214,412,000 | $233,782,000 |
| Performance Products | $73,533,000 | $80,179,000 | $67,534,000 | $75,382,000 | $75,694,000 | $67,074,000 | $59,038,000 | $62,239,000 |
By Geography (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| United States | $877,127,000 | $739,919,000 | $584,763,000 | $578,773,000 | $561,803,000 | $494,889,000 | $471,938,000 | $480,101,000 |
| Latin America and Canada | $340,668,000 | $298,649,000 | $247,705,000 | $219,846,000 | $191,047,000 | $166,325,000 | $158,939,000 | $152,380,000 |
| EMEA | $187,942,000 | $160,232,000 | $121,977,000 | $117,815,000 | $122,480,000 | $114,131,000 | $112,179,000 | — |
| Asia Pacific | $112,356,000 | $97,415,000 | $63,234,000 | $61,455,000 | $66,931,000 | $58,005,000 | $57,298,000 | $90,149,000 |
| Europe, Middle East and Africa | — | — | — | — | — | — | — | $105,365,000 |
By Product & Service (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Medicated Feed Additives and Others | $810,728,000 | $646,354,000 | $420,959,000 | $387,349,000 | $361,538,000 | $330,017,000 | $322,300,000 | $350,468,000 |
| Mineral Nutrition | $282,341,000 | $253,240,000 | $243,663,000 | $242,656,000 | $259,512,000 | $220,560,000 | — | — |
| Nutritional Specialties | $195,072,000 | $179,289,000 | $164,671,000 | $172,504,000 | $157,196,000 | $142,760,000 | $129,264,000 | $113,215,000 |
| Vaccines | $156,419,000 | $137,153,000 | $120,852,000 | $99,998,000 | $88,321,000 | $72,939,000 | $75,340,000 | $68,291,000 |
| Performance Products | $73,533,000 | $80,179,000 | $67,534,000 | $75,382,000 | $75,694,000 | $67,074,000 | — | — |